1. Academic Validation
  2. Potential therapeutic target of EGF on bile duct ligation model and biliary atresia children

Potential therapeutic target of EGF on bile duct ligation model and biliary atresia children

  • Pediatr Res. 2023 May 3. doi: 10.1038/s41390-023-02592-4.
Qipeng Zheng # 1 2 Mengdi Li # 1 2 Lingzhi Chen 1 2 Cong Zhang 1 2 Yilin Zhao 1 2 Gengxin Liu 1 2 Fang Yang 1 2 Jianghua Zhan 3
Affiliations

Affiliations

  • 1 Graduate College, Tianjin Medical University, Tianjin, 300070, China.
  • 2 Department of General Surgery, Tianjin Children's Hospital, Tianjin, 300134, China.
  • 3 Department of General Surgery, Tianjin Children's Hospital, Tianjin, 300134, China. zhanjianghuatj@163.com.
  • # Contributed equally.
Abstract

Background: The pathogenesis of liver fibrosis in biliary atresia (BA) is unclear. Epidermal growth factor (EGF) plays a vital role in liver fibrosis. This study aims to investigate the expression of EGF and the mechanisms of its pro-fibrotic effects in BA.

Methods: EGF levels in serum and liver samples of BA and non-BA children were detected. Marker proteins of EGF signaling and epithelial-mesenchymal transition (EMT) in liver sections were evaluated. Effects of EGF on intrahepatic cells and the underlying mechanisms were explored in vitro. Bile duct ligation (BDL) mice with/without EGF antibody injection were used to verify the effects of EGF on liver fibrosis.

Results: Serum levels and liver expression of EGF elevated in BA. Phosphorylated EGF receptor (p-EGFR) and extracellular regulated kinase 1/2 (p-ERK1/2) increased. In addition, EMT and proliferation of biliary epithelial cells were present in BA liver. In vitro, EGF induced EMT and proliferation of HIBEpic cells and promoted IL-8 expression in L-02 cells by phosphorylating ERK1/2. And EGF activated LX-2 cells. Furthermore, EGF antibody injection reduced p-ERK1/2 levels and alleviated liver fibrosis in BDL mice.

Conclusion: EGF is overexpressed in BA. It aggravates liver fibrosis through EGF/EGFR-ERK1/2 pathway, which may be a therapeutic target for BA.

Impact: The exact pathogenesis of liver fibrosis in BA is unknown, severely limiting the advancement of BA treatment strategies. This study revealed that serum and liver tissue levels of EGF were increased in BA, and its expression in liver tissues was correlated with the degree of liver fibrosis. EGF may promote EMT and proliferation of biliary epithelial cells and induce IL-8 overexpression in hepatocytes through EGF/EGFR-ERK1/2 signaling pathway. EGF can also activate HSCs in vitro. The EGF/EGFR-ERK1/2 pathway may be a potential therapeutic target for BA.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-112181
    99.61%, ERK1/2抑制剂
    ERK